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Introduction
Cancer in all forms causes 9% of deaths throughout 
the world. In the developed countries it is the second 
cause of death and in the developing countries it is ranked 
as the fourth cause of death. In Iran, cancer ranks as the 
third cause of death. Geographical, racial and habitual 
differences have led to the variation in the incidence of 
cancer in different regions of this country. The second 
most prevalent types of cancer in Iran are lymphoma 
and leukemia (L&L). The estimated incidence of L&L in 
1952 was 0.66 per 100,000 population and 5.9/100,000 
during 1987-2003 in Mazandaran province (the highest 
incidence rate was observed in Babol (7.29) and the least 
was equally calculated in Neka and Tonekabon (1.47) 
(Tahmasebi et al., 2008).
Lymphoma is the third most common cancer among 
children in USA, with an annual incidence of 15 per 
million children < 14 yr of age (Cairo and Bradley, 2007). 
Lymphomas are malignancies of the lymphoid cells and 
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Abstract
 Introduction: Malignancies of lymphoid cells can be divided into Hodgkin and non-Hodgkin lymphomas 
(NHL) on the basis of pathologic features, clinical manifestations and treatment. In this paper we present data 
on lymphomas in Golestan province, in the northeast of Iran, during 2004-2006, using three years results of 
the Golestan population-based cancer registry (GPCR),  a voting member of the International Association of 
Cancer Registries (IACR). Methods: GPCR started collecting data on all cancers from all public and private 
diagnostic and therapeutic centers (hospitals, specialist physicians’ offices, pathology, laboratory, and imaging 
centers) of Golestan province in 2004. Here, we used the Iranian national census data to identify the population 
characteristics of this geographical area. The last census was done in 2006 and the next one will be done in 2011. 
The population data for years between the national census intervals are retrieved from provincial census done 
annually by health deputy of Golestan University of Medical Sciences (GOUMS). Results: A total of 5,076 cancer 
cases were diagnosed in the GPCR between 2004 and 2006. Of these, 237 (4.67 %) were lymphomas,  among the 
ten top cancers of this area, the patients having a mean (±SD) age of 45.2 (±20.9) years. The number of cases, 
frequency, age specific rates, crude rates and age standardized incidence rates (ASR) (per 100,000 person-
years) for lymphomas in males and females are presented. Conclusion:  It could be concluded that according 
to available therapies for HL and NHL, the outcome of the patients could be improved in this area, due to the 
better diagnostic and therapeutic methods now available.
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can be divided into Hodgkin and non-Hodgkin lymphomas 
(NHL) regarding with the basis of pathologic features, 
clinical manifestations and treatment. The latter is an 
umbrella designation for at least 30 types of distinct B- and 
T-cell neoplasms. Although it was recently determined to 
be a B-cell lymphoma, Hodgkin lymphoma or Hodgkin’s 
disease differs substantially from other lymphomas with 
respect to epidemiologic and survival characteristics. 
Altogether, NHLs are substantially more common and, 
when grouped together as a single entity, represent one of 
the top five sources of cancer morbidity and mortality in 
the US population (Clarke and O’Malley). The incidence 
of NHL and the pattern of expression of the various 
subtypes differ geographically. T cell lymphomas are 
more common in Asia than in western countries, while 
certain subtypes of B cell lymphomas such as follicular 
lymphomas are more common in western countries 
(Armitage and Longo, 2005). NHLs are also a growing 
component of the cancer burden; incidence rates increased 
over 80% between 1973 and 1999 as one of the most 
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rapid increases observed among all cancers (Clarke and 
O’Malley). NHL accounts for approximately 60% of all 
lymphomas in children and adolescents. It represents 
8-10% of all malignancies in children between 5-19 yr of 
age, with an annual incidence of 750-800 cases per year in 
USA in children < 19 yr of age. Although >70% of patients 
present with advanced disease at diagnosis, the prognosis 
has improved dramatically, with survival rates of 90-95% 
for localized disease and 60-90% with advanced disease 
(Cairo and Bradley, 2007). The estimated incidence of 
10.2 cases per 1,000,000 children-years {95% Confidence 
Intervals (CI), 8.4-12.1} in Greece is around the average 
figure in countries of the European Union (Petridou et al., 
2007). In Berlin-Frankfurt-Münster during 1986-2002 
only 20 (1%) infants with NHL was identified (Mann et 
al., 2007). Some of the rapid increase in NHL incidence 
can be attributed to improvements in diagnostic practice 
and disease classifications, as well as to the HIV epidemic, 
as NHL is at least 100-times more likely to occur in the 
context of HIV-related immunosuppression. However, 
other reasons for the increasing incidence remain unclear. 
Overall, more than half of the patients diagnosed with 
NHL survive five years after diagnosis. Age influenced 
survival strongly as older persons typically experienced 
poorer survival, and even within stage, older persons had 
lower survival rates. Although, NHL incidence rates were 
higher in males than females across the age spectrum and 
females had slightly higher survival rates. As with most 
cancers, stage at diagnosis exerted considerable impact on 
survival. The presence of B-symptoms (B-symptoms mean 
the constitutional symptoms like fever, chills and weight 
loss) dramatically lowered survival within all stage and age 
groups (Armitage and Longo, 2005). Hodgkin Lymphoma 
(HL) is a cancer of the lymphoid cells with which an 
estimated 7,800 persons are diagnosed each year in the 
United States (American Cancer Society, 2006). Although 
it is a relatively rare cancer in the general population, it 
is one of the most common cancers diagnosed in young 
persons. A hallmark feature of HL epidemiology is its 
bimodal age-specific incidence pattern, in which incidence 
is highest between the ages of 15 and 34 years, declines 
between ages 35 and 54 years and increases again after the 
age of 55 years (Clarke et al). HL is a malignant process 
of the lympho-reticular system that constitutes 6% of 
childhood cancers. In the USA, HL accounts for about 5% 
of cancers in persons< 14 yr of age and for about 15% in 
15-19 yrs-olds. It is rare in children<10 yr of age (Cairo 
and Bradley, 2007). In developed nations, HL is rare in 
<5-year olds and represents a minority in developing 
countries (Belgaumi et al., 2008). HL is more common 
in whites than in blacks and more common in males than 
in females (Armitage and Longo, 2005). 
In this paper we will present the data of lymphomas 
in Golestan province, northeast of Iran, during 2004-
2006, using the three years results of the Golestan 
population based cancer registry (GPCR) (Semnani et 
al., 2005). GPCR has been known as a voting member of 
the international association of cancer registries (IACR) 
(Semnani et al., 2008). 
Materials and Methods
GPCR has started data gathering from 2004. It is a 
population based cancer registry. In the other hand, we 
collect data on all cancers from all public and private 
diagnostic and therapeutic centers (hospitals, specialist 
physicians’ offices, pathology, laboratory, and imaging 
centers) of Golestan province, Northeast of Iran. We use 
the Iranian national census data to identify the population 
characteristics of this geographical area. The last census 
was done in 2006 and the next one will be done in 2011. 
The population data for years between the national 
census intervals are retrieved from provincial census 
done annually by health deputy of Golestan University 
of Medical Sciences (GOUMS).
We use two kinds of questionnaires, the first for 
outpatient and the second for inpatient cases. These 
questionnaires have been prepared based on IACR 
standards. Items collected in GPCR are consisted of the 
patient’s demographic characteristics (first name, last 
name, father’s name, sex, age, ethnicity, marital status, 
address and phone number), anatomical site of cancer, 
histology of tumor, method of diagnosis, date of diagnosis, 
method of treatment and outcome (date of death). 
In some centers the data are collected passively i.e., 
notifications of diagnosed cases are sent to the registry 
on a routine, continuing basis. In these centers, an expert 
healthcare worker was selected and participated in 
professional workshops to learn how to collect requested 
data. Data collection in other centers is active, that means 
the registry stuffs regularly visit them and get information 
of cancer cases. Usually 10% of questionnaires are 
checked and compared with original documents in the 
referral centers to see if the abstraction process was 
accurate and complete. We regularly get information 
of cancer related deaths from death registry of health 
department of GOUMS and match this data with the file 
of registered cancer patients to identify unreported cases 
(Death Certificate Only or DCO cases).
We use the third edition of International Classification 
Table 1. Characteristics of Patients with Lymphoma in 
Golestan Province of Iran during 2004-2006
Variable Number Percent
Sex
  Male 157 66.2
  Female   80 33.8
Place of residence
  Urban 174 73.42
  Rural   63 26.58
Age groups (years)
  <10     7 3.0
  10-19   29 12.2
  20-29   28 11.8
  30-39   31 13.1
  40-49   32 13.5
  50-59   43 18.1
  60-69   27 11.4
  >70   40 16.9
Method of diagnosis
  Clinical only     1 0.4
  Para-clinical     4 1.7
  Histology 232 97.9
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of Childhood Cancer (ICCC-3), coding system, which 
applies the rules, nomenclature and codes (morphology, 
topography, and behavior) of the third edition of the 
International Classification of Diseases for Oncology 
(ICD-O-3). IARC multiple primary rules(11) are used 
for patients with malignant tumors in more than one site.
Data are entered into CanReg-4 software, created and 
published by IARC. Finally, numbers of cases by sex, age 
and primary site as well as age standardized incidence rates 
(ASR) and mortality rates for all cancers are calculated 
and reported annually.
Results
Totally 5076 cancer cases were diagnosed in GPCR 
between 2004 and 2006. Of these, 237 (4.67 %) were 
lymphomas with mean (±SD) age of 45.22 (±20.94) 
years. Lymphoma was among the ten top cancers of 
this area. Table 1 shows the characteristics of patients 
with lymphoma in Golestan province during 2004-2006. 
Number of cases, frequency, age specific rates, crude rates 
and age standardized incidence rates (ASR) (per 1000000 
person-years) for lymphomas in males and females are 
shown in Tables 2 and 3, respectively.
Discussion
According to the results, lymphoma was among the 
first ten cancers diagnosed in both genders during this 
3-years-period (eighth in men and tenth in women).
As seen in Table 2 and 3, ASRs of lymphomas (NHL 
and HL) were 8.4/ 100000 and 4.2/100000 in males and 
females, respectively. Other studies in the Mazandaran 
province (neighboring province of Golestan) reported 
an ASR of 5.9/100000 during 1987-2003 which showed 
an increase from 0.66/100000 in 1952 in that area 
(Tahmasebi et al., 2008). In comparison to the whole 
country, lymphoma is ranked lower in our area and its 
prevalence in males seems to be higher compared to the 
next door province. Both NHL and HL have a higher age 
specific incidence rate in males compared to females of 
Golestan province.
Other reports documented this predominance in male 
and they also reported a higher survival rate in women 
(Armitage and Longo, 2005; Clarke et al). Similar to other 
studies (Clarke et al), HL had two peak rates, one between 
15-34 years age group and the other in cases older than 
55-years-old. Despite its relatively low level of occurrence 
and high curability, it is the propensity of HL to occur 
in the productive years of life that makes it a significant 
source of cancer-related morbidity and mortality in the 
US (Mauch et al., 1993). 
In our studied cases, children 0-14-years-old had the 
lowest ASR of both HL and NHL among all age groups 
(2/100000 in males and 0 in females). NHL has an annual 
incidence of 750-800 cases per year in USA and an 
estimated incidence of 10.2 cases per 1000000 children-
years in Greece (Cairo and Bradley, 2007; Petridou et 
al., 2007).
HL is reported rare in <5-year olds in developed 
nations and represents minority in developing countries 
(Cairo and Bradley, 2007; Belgaumi et al., 2008). Several 
probable risk factors are mentioned for lymphoma, some 
are as followings: genetic susceptibility (Pang et al., 
2008), long-term use of tricyclic antidepressants (Dalton 
et al., 2008), blood transfusions and chronic diseases as 
Rheumatoid Arthritis (Cerhan et al., 2008; Smitten et al., 
2008), large sib ship size, late birth order, and childhood 
crowding (Smedby et al., 2007). In contrast better hygiene 
and sanitation, decreasing family size, sun exposure of 
children (Petridou et al., 2007) and high dietary intake 
of vitamin D can decrease the incidence of non-Hodgkin 
lymphoma (NHL) around the world (Armstrong and 
Kricker, 2007). It is clear that most of these risk factors are 
preventable. HL is also notable among other cancers for 
the availability of curative therapy, which has resulted in 
relatively favorable outcomes; the rate of one-year relative 
survival for HL was generally favorable at 92% in other 
studies (Clarke et al.; Ries et al., 2006). 
Here we could not retrieve stages of the disease and 
related survival rate, thus other detailed researches are 
suggested to follow cases diagnosed with lymphoma and 
assess the related risk factors between males and females 
in different age groups.
Thus, it could be concluded that according to available 
therapies for HL and NHL, the outcome of the patients 
could be improved in this area, due to the better diagnostic 
and therapeutic methods now available in the area.
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